Medicalisation of race.
Duster
Troy
T
New York University, New York, NY 10003, USA. troy.duster@nyu.edu
D001741:Black or African American / Q000235:genetics*; D017677:Age Distribution; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004338:Drug Combinations; D000077156:Gefitinib; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D011799:Quinazolines / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D004338:Drug Combinations; D011799:Quinazolines; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate; D000077156:Gefitinib